Presentations and Results from the 2016 Hexima Limited Annual General Meeting
NOTICE IS GIVEN that the Annual General Meeting of the ordinary shareholders of Hexima Limited
Click here to view the October 2016 shareholder update presentation.
Hexima’s Annual Financial Report for the year ended 30 June 2016
Shares in Hexima Limited are not traded on the ASX. The last off-market transfer of shares registered by the Company, as at the close of business on 30 June 2016, was at the price of $0.20 per share.
Hexima’s Chief Science Officer, Professor Marilyn Anderson, Onychomycosis Project Leader, Dr Michael Baker and Researcher, Dr Brigitte Hayes, have presented Hexima’s human antifungal technology at ASM Microbe 2016. The conference is an opportunity to showcase the benefits of Hexima’s technology and our progress towards clinical trials for fungal nail infections (onychomycosis). PhD Student Kathy Parisi also presented work relating to Hexima’s antifungal technology.
Shareholder Update Newsletter – June 2016
Hexima has executed its first commercial licence for Multi-Gene Expression Vehicle (MGEV) technology. This is an exciting milestone for the company. Long term collaborator DuPont Pioneer has exercised its commercial option under an existing research licence to develop products via this technology.
Please click here to read the latest Chairman’s Letter to Shareholders. This update outlines the latest progress on the HXP124 onychomycosis project and Hexima’s plans for proceeding to human clinical trials.